STOCK TITAN

Rain Oncology Inc - RAIN STOCK NEWS

Welcome to our dedicated news page for Rain Oncology (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rain Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rain Oncology's position in the market.

Rhea-AI Summary
Pathos AI, Inc. successfully completed the acquisition of Rain Oncology Inc. at $1.16 per share in cash plus one contingent value right per share. The tender offer saw 28,031,182 shares of Rain common stock tendered, representing approximately 77% of the outstanding shares. Following the merger, Rain became a wholly owned subsidiary of Pathos, and its shares ceased trading on Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition AI
-
Rhea-AI Summary
Rain Oncology Inc. (Nasdaq: RAIN) has entered into a definitive merger agreement with Pathos AI, Inc. for $1.16 in cash per share plus a non-tradeable contingent value right (CVR) for potential cash payments of up to approximately $0.17 per share. The upfront cash consideration represents a 17% premium over Rain’s unaffected stock price as of October 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
acquisition AI
-
Rhea-AI Summary
Rain Oncology Inc. (NasdaqGS: RAIN) reported Q3 2023 financial results, with a net loss of $7.0 million. R&D expenses decreased due to the winding down of clinical trials, while G&A expenses increased. Rain had $77.3 million in cash and approximately 36.4 million shares of common stock outstanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
earnings
Rhea-AI Summary
Rain Oncology Inc. (NasdaqGS: RAIN) reports financial results for Q2 2023, with a quarter-end cash position of $86.3 million. The company is evaluating opportunities to diversify its pipeline in precision oncology and has submitted data abstracts for milademetan in MANTRA and MANTRA-2 clinical studies. Rain's management aims to add value to shareholders through licensing or acquiring clinical-stage programs and partnering with companies using proprietary technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
earnings
-
Rhea-AI Summary
Rain Oncology Inc. (NasdaqGS: RAIN) will report Q2 2023 financial results and provide a corporate update on August 10, 2023. The management will host a conference call and webcast to discuss business and financial results. Dial-in numbers and webcast link provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
Rhea-AI Summary
Rain Oncology Inc. announces topline Phase 3 MANTRA trial data for milademetan in patients with dedifferentiated liposarcoma. The trial did not meet its primary endpoint of progression free survival compared to standard of care trabectedin. Rain does not expect to pursue further development of milademetan in this indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-87.71%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.95%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
Rain Oncology Inc

Nasdaq:RAIN

RAIN Rankings

RAIN Stock Data

44.01M
14.58M
16.48%
68.39%
1.82%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Newark

About RAIN

rain therapeutics is a san francisco bay area-based biotechnology company, focused on developing small molecule targeted therapeutics for cancer patients that possess a clear, and single, oncogenic driver.